Stockscreener 앱 받기
0.36
0.00%
0.00
전일 마감가:
$0.36
열려 있는:
$0.374
하루 거래량:
66,007
Relative Volume:
0.44
시가총액:
$22.62M
수익:
$37.20M
순이익/손실:
$-11.85M
주가수익비율:
-1.8868
EPS:
-0.1908
순현금흐름:
$-10.59M
1주 성능:
-5.29%
1개월 성능:
-0.55%
6개월 성능:
-46.82%
1년 성능:
-61.85%
1일 변동 폭
$0.3502
$0.3846
1주일 범위
$0.3502
$0.401
52주 변동 폭
$0.35
$1.22
Cytosorbents Corp Stock (CTSO) Company Profile
명칭
Cytosorbents Corp
전화
973-329-8885
주소
305 COLLEGE ROAD EAST, PRINCETON, NJ
Compare CTSO vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CTSO
Cytosorbents Corp
|
0.36 | 22.62M | 37.20M | -11.85M | -10.59M | -0.1908 |
ABT
Abbott Laboratories
|
104.49 | 182.00B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
336.74 | 129.09B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
84.22 | 107.81B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
45.51 | 67.64B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
83.04 | 47.81B | 6.30B | 1.07B | 1.09B | 1.8406 |
Cytosorbents Corp Stock (CTSO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-09-07 | 개시 | B. Riley Securities | Buy |
| 2021-10-14 | 재개 | B. Riley Securities | Buy |
| 2020-09-17 | 개시 | Jefferies | Buy |
| 2020-09-01 | 개시 | SVB Leerink | Outperform |
| 2017-08-08 | 재확인 | Maxim Group | Buy |
| 2016-10-26 | 개시 | Aegis Capital | Buy |
| 2016-05-24 | 개시 | Maxim Group | Buy |
| 2015-10-29 | 업그레이드 | WBB Securities | Speculative Buy → Buy |
| 2015-05-12 | 재확인 | MLV & Co | Buy |
| 2015-04-01 | 재확인 | MLV & Co | Buy |
| 2015-03-05 | 개시 | MLV & Co | Buy |
| 2015-02-25 | 개시 | WBB Securities | Speculative Buy |
| 2015-01-27 | 재확인 | H.C. Wainwright | Buy |
모두보기
Cytosorbents Corp 주식(CTSO)의 최신 뉴스
Cytosorbents Corp (CTSO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cytosorbents Corp (CTSO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CytoSorbents Market Sentiment - Benzinga España
Cytosorbents Corp (CTSO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CTSO|Cytosorbents Corp|Price:0.360|Chg%:-0.001 - TradingKey
TradingKey - TradingKey
Cytosorbents Corp (CTSO) Cash Flow - TradingKey
CTSO|Cytosorbents Corp|Price:0.360| - TradingKey
Cytosorbents Corp (CTSO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cytosorbents Corp (CTSO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
CytoSorbents to Report Second Quarter 2026 Financial Results and Recent Business Highlights - BioSpace
CytoSorbents (CTSO) to Release Q2 Financial Results on July 30 - GuruFocus
CytoSorbents Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
CytoSorbents (NASDAQ: CTSO) falls below Nasdaq $35M value test, faces 180-day cure - Stock Titan
CTSO | Cytosorbents Corp. Executive Compensation - Quiver Quantitative
[ARS] Cytosorbents Corp SEC Filing - Stock Titan
CytoSorbents (NASDAQ: CTSO) seeks reverse split to support Nasdaq listing - Stock Titan
CytoSorbents (NASDAQ: CTSO) Targets Major ICU & Cardiac Surgery Markets With Breakthrough Blood Purification Tech, Eyes 2026 Cash Flow Breakeven and FDA Approval 246 - Minichart
CytoSorbents schedules two FDA pre-submission meetings for ticagrelor and DOAC programs - TradingView
CytoSorbents (NASDAQ: CTSO) details DrugSorb-ATR FDA meetings, sales and cash flow goals - Stock Titan
Cytosorbents Corp (CTSO) Institutional Confidence - TradingKey
CytoSorbents to Present at the Life Sciences Forum on June 24, 2026 and Meet Virtually with Investors on June 30, 2026 - Yahoo Finance
Cytosorbents Corp (CTSO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cytosorbents Corp (CTSO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cytosorbents Corp (CTSO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cytosorbents (CTSO) Drops 9% as Shares Test Key Support at $0.45PCR Mean Reversion - dars.gov.et
Cytosorbents CFO Peter Mariani buys $44,000 in stock - Investing.com UK
Cytosorbents CFO Peter Mariani buys $44,000 in stock By Investing.com - Investing.com India
Cytosorbents (CTSO) CFO Peter Mariani buys 100,000 shares in open market - Stock Titan
Cytosorbents CEO Phillip Chan buys $104,897 in company stock - Investing.com
CTSO | Cytosorbents Corp. FinancialsIncome Statement - Quiver Quantitative
Cytosorbents (CTSO) CEO boosts stake with 261,469-share open-market buy - Stock Titan
Cytosorbents (CTSO) Q1 2026 Earnings: EPS Miss Overshadows Progress, Yet Stock Gains 3%Pre-Announcement Alert - DonanımHaber
Cytosorbents Corporation (NASDAQ:CTSO): Is Breakeven Near? - simplywall.st
CytoSorbents (NASDAQ: CTSO) asks shareholders to OK 1-for-5–1-for-20 reverse split - Stock Titan
CytoSorbents Corp stock (US23283M1018): Q1 miss keeps focus on growth and cash runway - AD HOC NEWS
CTSO Technical Analysis & Stock Price Forecast - Intellectia AI
CytoSorbents Corp stock (US23283M1018): analyst sentiment and low share price keep focus on Nasdaq-l - AD HOC NEWS
CytoSorbents Corp stock (US23283M1018): Nasdaq price action and valuation metrics in focus - AD HOC NEWS
CTSOCytosorbents Corp Stock Price and Quote - Finviz
Cytosorbents Earnings Call Balances Progress and Pressure - The Globe and Mail
Why Cytosorbents (CTSO) Just Dropped -1.78% — What to Watch 2026-05-20Expert Momentum Signals - Newser
Earnings call transcript: CytoSorbents Q1 2026 misses forecasts, stock falls - Investing.com
Cytosorbents (CTSO) Q1 2026 Disappoints — EPS $-0.08 Below $-0.06 ViewsDividend Growth Analysis - Newser
Cytosorbents Corporation (NASDAQ:CTSO) Q1 2026 Earnings Call Transcript - Insider Monkey
Cytosorbents Earnings Call Balances Progress And Pressure - The Globe and Mail
CytoSorbents Reports First Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update - BioSpace
CytoSorbents Corp (CTSO) Q1 2026 Earnings Call Highlights: Navigating Challenges with Strategic Growth - GuruFocus
Is CytoSorbents (CTSO) a Value Trap Despite 39.9% Undervaluation - GuruFocus
CytoSorbents (CTSO) Reports Q1 Revenue Growth - GuruFocus
Transcript: CytoSorbents Q1 2026 Earnings Conference Call - Yahoo Finance
Cytosorbents Corp (CTSO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.79%
4.39%
자본화:
|
볼륨(24시간):